February 6, 2025 India's Aurobindo Pharma posts third-quarter profit drop on higher expenses Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in ...
Aurobindo Pharma subsidiary Auro Vaccines has terminated a pentavalent vaccine candidate licence agreement with Hilleman Laboratories Singapore. The September 2023 agreement envisaged developing ...
“The inspection concluded with 5 observations. The observations are procedural in nature and will be responded to within the stipulated time,’‘ Aurobindo Pharma said on Tuesday.
Shares of Aurobindo Pharma tumbled 9.5 percent to Rs 1,053 on February 19 after the US FDA completed a pre-approval inspection of its subsidiary, Eugia Steriles, issuing five procedural observations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback